diabetic nephropathies

Summary

Summary: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.

Top Publications

  1. pmc Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
    Toshiharu Ninomiya
    George Institute for International Health, University of Sydney, Sydney, NSW, Australia
    J Am Soc Nephrol 20:1813-21. 2009
  2. ncbi Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 345:861-9. 2001
  3. ncbi Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)
    Amanda I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, and South Cleveland Hospital, Cleveland, United Kingdom
    Kidney Int 63:225-32. 2003
  4. pmc Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
  5. pmc A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells
    Mitsuo Kato
    Gonda Diabetes Center, Beckman Research Institute of the City of Hope, Duarte, California, USA
    Kidney Int 80:358-68. 2011
  6. ncbi Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
    N J Morrish
    North Bedfordshire Diabetes Centre, Bedford Hospital, UK
    Diabetologia 44:S14-21. 2001
  7. pmc MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors
    Mitsuo Kato
    Gonda Diabetes Center, Division of Molecular Biology, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Proc Natl Acad Sci U S A 104:3432-7. 2007
  8. ncbi From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy
    Gunter Wolf
    Renal Electrolyte and Hypertension Division, University of Pennsylvania, 700 Clinical Research Building, 415 Curie Blvd, Philadelphia, PA 19104 4218, USA
    Diabetes 54:1626-34. 2005
  9. ncbi Glycemic status and development of kidney disease: the Framingham Heart Study
    Caroline S Fox
    National Heart, Lung, and Blood Institute s Framingham Heart Study, 73 Mt Wayte Ave Suite 2, Framingham, Massachusetts 01702, USA
    Diabetes Care 28:2436-40. 2005
  10. ncbi Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
    Douglas S Keith
    Division of Nephrology and Hypertension, Oregon Health and Science University, USA
    Arch Intern Med 164:659-63. 2004

Detail Information

Publications415 found, 100 shown here

  1. pmc Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
    Toshiharu Ninomiya
    George Institute for International Health, University of Sydney, Sydney, NSW, Australia
    J Am Soc Nephrol 20:1813-21. 2009
    ..In conclusion, high albuminuria and low eGFR are independent risk factors for cardiovascular and renal events among patients with type 2 diabetes...
  2. ncbi Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    B M Brenner
    Renal Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 345:861-9. 2001
    ..We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy...
  3. ncbi Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)
    Amanda I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, and South Cleveland Hospital, Cleveland, United Kingdom
    Kidney Int 63:225-32. 2003
    ..This study sought to describe the development and progression through the stages of microalbuminuria, macroalbuminuria, persistently elevated plasma creatinine or renal replacement therapy (RRT), and death...
  4. pmc Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  5. pmc A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells
    Mitsuo Kato
    Gonda Diabetes Center, Beckman Research Institute of the City of Hope, Duarte, California, USA
    Kidney Int 80:358-68. 2011
    ..Thus, miRNA-regulated circuits may amplify TGF-β1 signaling, accelerating chronic fibrotic diseases such as diabetic nephropathy...
  6. ncbi Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
    N J Morrish
    North Bedfordshire Diabetes Centre, Bedford Hospital, UK
    Diabetologia 44:S14-21. 2001
    ..The low excess mortality in the Japanese cohort could have implications for the possible reduction of the burden of mortality associated with diabetes in other parts of the world...
  7. pmc MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors
    Mitsuo Kato
    Gonda Diabetes Center, Division of Molecular Biology, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Proc Natl Acad Sci U S A 104:3432-7. 2007
    ..These results uncover a role for miRs in the kidney and DN in controlling TGF-beta-induced Col1a2 expression by down-regulating E-box repressors...
  8. ncbi From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy
    Gunter Wolf
    Renal Electrolyte and Hypertension Division, University of Pennsylvania, 700 Clinical Research Building, 415 Curie Blvd, Philadelphia, PA 19104 4218, USA
    Diabetes 54:1626-34. 2005
    ..The mainstays of therapy, glycemic control and inhibition of ANG II, are key measures to prevent early podocyte injury and the subsequent development of diabetic nephropathy...
  9. ncbi Glycemic status and development of kidney disease: the Framingham Heart Study
    Caroline S Fox
    National Heart, Lung, and Blood Institute s Framingham Heart Study, 73 Mt Wayte Ave Suite 2, Framingham, Massachusetts 01702, USA
    Diabetes Care 28:2436-40. 2005
    ..Diabetes is a major risk factor for the development of kidney disease and is the leading cause of end-stage renal disease in the U.S. Whether pre-diabetes is associated with the development of kidney disease is unclear...
  10. ncbi Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
    Douglas S Keith
    Division of Nephrology and Hypertension, Oregon Health and Science University, USA
    Arch Intern Med 164:659-63. 2004
    ..The purpose of this study was to understand the natural history of chronic kidney disease with regard to progression to renal replacement therapy (transplant or dialysis) and death in a representative patient population...
  11. pmc Renal and retinal effects of enalapril and losartan in type 1 diabetes
    Michael Mauer
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    N Engl J Med 361:40-51. 2009
    ..Nephropathy and retinopathy remain important complications of type 1 diabetes. It is unclear whether their progression is slowed by early administration of drugs that block the renin-angiotensin system...
  12. doi Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome
    Zhi Feng Luo
    Institute of Nephrology of Chongqing and Department of Nephrology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, People s Republic of China
    Life Sci 88:512-20. 2011
    ..We aimed to investigate whether inhibiting the proteasome has a preventive effect on DN through suppression of renal oxidative stress...
  13. ncbi Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
    Mark J Sarnak
    Circulation 108:2154-69. 2003
  14. ncbi An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study
    A Y T Wu
    Wu Nephrology and Medical Clinic, Mount Elizabeth Medical Center, 3 Mount Elizabeth, 2258510, Singapore
    Diabetologia 48:17-26. 2005
    ..There is limited information on the prevalence of microalbuminuria among hypertensive type 2 diabetic patients in Asia...
  15. ncbi Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    E J Lewis
    Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA
    N Engl J Med 345:851-60. 2001
    ..CONCLUSIONS: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes...
  16. ncbi Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy
    Katalin Susztak
    Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Diabetes 55:225-33. 2006
    ....
  17. ncbi Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74
    Ravi Retnakaran
    Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Diabetes 55:1832-9. 2006
    ..Distinct sets of risk factors are associated with the development of these two outcomes, consistent with the concept that they are not linked inexorably in type 2 diabetes...
  18. pmc Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study
    Mark E Molitch
    Northwestern University, Chicago, Illinois, USA
    Diabetes Care 33:1536-43. 2010
    ..73 m(2) in type 1 diabetes up to year 14 of the Epidemiology of Diabetes Interventions and Complications (EDIC) study (mean duration of 19 years in the Diabetes Control and Complications Trial [DCCT]/EDIC)...
  19. pmc Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice
    Jinhua Li
    Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria 3800, Australia
    Am J Pathol 175:1380-8. 2009
    ....
  20. doi Clinical review: The role of advanced glycation end products in progression and complications of diabetes
    Su Yen Goh
    Albert Einstein Juvenile Diabetes Research Foundation, Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Medical Research Institute, Melbourne, Victoria, Australia 8008
    J Clin Endocrinol Metab 93:1143-52. 2008
    ....
  21. pmc The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy
    Tao Jiang
    Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona, USA
    Diabetes 59:850-60. 2010
    ..Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis. Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy...
  22. pmc Mouse models of diabetic nephropathy
    Frank C Brosius
    University of Michigan, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0680, USA
    J Am Soc Nephrol 20:2503-12. 2009
    ..Nonetheless, the critical analysis of existing murine models substantially enhances our understanding of this disease process...
  23. pmc Diabetic neuropathy: mechanisms to management
    James L Edwards
    Department of Neurology, The University of Michigan, Ann Arbor, MI 48109, USA
    Pharmacol Ther 120:1-34. 2008
    ..This review covers the pathology, epidemiology, biochemical pathways, and prevention of diabetic neuropathy, as well as discusses current symptomatic and causal therapies and novel approaches to identify therapeutic targets...
  24. pmc Vegfa protects the glomerular microvasculature in diabetes
    Gavasker A Sivaskandarajah
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Diabetes 61:2958-66. 2012
    ..These results suggest that upregulation of VEGFA in diabetic kidneys protects the microvasculature from injury and that reduction of VEGFA in diabetes may be harmful...
  25. pmc Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy
    Hongting Zheng
    Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona, USA
    Diabetes 60:3055-66. 2011
    ..To determine whether dietary compounds targeting NFE2-related factor 2 (Nrf2) activation can be used to attenuate renal damage and preserve renal function during the course of streptozotocin (STZ)-induced diabetic nephropathy...
  26. ncbi Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy
    Takahiko Nakagawa
    Division of Nephrology, Hypertension and Transplantation, University of Florida, PO Box 100224, Gainesville, FL 32610 0224, USA
    J Am Soc Nephrol 18:539-50. 2007
    ..It was postulated that endothelial dysfunction should predict nephropathy and that correction of the dysfunction may prevent these important complications...
  27. pmc Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice
    S Ghosh
    Dept of Anaesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, Univ of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3
    Am J Physiol Renal Physiol 296:F700-8. 2009
    ..Reductions in caspase-3 and caspase-8 activities, with parallel improvements in SOD expression and reduced oxidative damage, could underlie the beneficial effects of exercise in diabetic kidney disease...
  28. ncbi Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
    Dick de Zeeuw
    Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
    Kidney Int 65:2309-20. 2004
    ....
  29. ncbi Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy
    Takamichi Ito
    Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
    Nephrology (Carlton) 11:29-35. 2006
    ....
  30. ncbi Nephropathy in diabetes
    Mark E Molitch
    Diabetes Care 27:S79-83. 2004
  31. doi Pathologic classification of diabetic nephropathy
    Thijs W Cohen Tervaert
    Department of Pathology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Am Soc Nephrol 21:556-63. 2010
    ..of the Renal Pathology Society, was to develop a consensus classification combining type1 and type 2 diabetic nephropathies. Such a classification should discriminate lesions by various degrees of severity that would be easy to ..
  32. pmc MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy
    Qiang Wang
    Section of Nephrology, Department of Medicine, The University of Chicago, 5841 South Maryland Ave, MC5100, AMB S523, Chicago, IL 60637, USA
    FASEB J 22:4126-35. 2008
    ..Thus, overexpression of miR-377 in diabetic nephropathy indirectly leads to increased fibronectin protein production; as such, miR-377 can have a critical role in the pathophysiology of this prevalent human disease...
  33. pmc RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
    Thoralf M Wendt
    Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Am J Pathol 162:1123-37. 2003
    ....
  34. pmc MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy
    Jianyin Long
    Division of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Biol Chem 286:11837-48. 2011
    ..These findings identify miR-29c as a novel target in diabetic nephropathy and provide new insights into the role of miR-29c in a previously unrecognized signaling cascade involving Spry1 and Rho kinase activation...
  35. ncbi Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease
    Emilio D Poggio
    Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, A51, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Am Soc Nephrol 16:459-66. 2005
    ..This study also emphasizes the complexity of laboratory calibration of serum creatinine measurements, a determining factor when estimating GFR in both healthy individuals and CKD patients with preserved GFR...
  36. pmc Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes
    Marcus G Pezzolesi
    Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 58:1403-10. 2009
    ..To search for genes that contribute to diabetic nephropathy, a genome-wide association scan was implemented on the Genetics of Kidneys in Diabetes collection...
  37. doi Insulin signaling to the glomerular podocyte is critical for normal kidney function
    Gavin I Welsh
    Academic Renal Unit, School of Clinical Sciences, University of Bristol, Bristol BS8 1TH, UK
    Cell Metab 12:329-40. 2010
    ..Collectively, this work reveals the critical importance of podocyte insulin sensitivity for kidney function...
  38. doi Oxidative stress as a major culprit in kidney disease in diabetes
    Josephine M Forbes
    Juvenile Diabetes Research Foundation Albert Einstein Centre for Diabetes Complications, Division of Diabetes and Metabolism, Baker Heart Research Institute, Melbourne, Australia
    Diabetes 57:1446-54. 2008
    ....
  39. pmc mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
    Ken Inoki
    Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Clin Invest 121:2181-96. 2011
    ..These results indicate that mTORC1 activation in podocytes is a critical event in inducing DN and suggest that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent DN...
  40. ncbi Extracellular matrix metabolism in diabetic nephropathy
    Roger M Mason
    Cell and Molecular Biology Section, Division of Biomedical Sciences, Faculty of Medicine, Imperial College London, Exhibition Road, London SW7 2AZ, UK
    J Am Soc Nephrol 14:1358-73. 2003
    ..This in turn leads to change in the expression of genes encoding extracellular matrix proteins and the protease systems responsible for their turnover...
  41. pmc Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice
    Hui John Zhao
    Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, C 3121 MCN, Nashville, TN 37232, USA
    J Am Soc Nephrol 17:2664-9. 2006
    ..In summary, eNOS(-/-) db/db mice provide the most robust model of type II DN that has been described to date and support a role for deficient eNOS-derived NO production in the pathogenesis of DN...
  42. pmc Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy
    Aleksandra Krupa
    Institute of Nephrology, Cardiff University, Heath Park Campus, Cardiff, UK
    J Am Soc Nephrol 21:438-47. 2010
    ..In summary, loss of miR-192 expression associates with increased fibrosis and decreased estimated GFR in diabetic nephropathy in vivo, perhaps by enhancing TGF-beta-mediated downregulation of E-cadherin in PTCs...
  43. ncbi Pathogenetic mechanisms of diabetic nephropathy
    Francesco P Schena
    Department of Emergency and Organ Transplantation, Renal Unit, University of Bari, Bari, Italy
    J Am Soc Nephrol 16:S30-3. 2005
    ....
  44. ncbi Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats
    Nuria Lloberas
    Nephrology Service, Hospital Universitari de Bellvitge, Feixa Llarga s n, 08907 L Hospitalet de Llobregat, Catalonia, Spain
    J Am Soc Nephrol 17:1395-404. 2006
    ..In conclusion, mTOR blockade by low-dose SRL has a beneficial effect in diabetic kidney disease, suggesting that the mTOR pathway has an important pathogenic role in diabetic nephropathy...
  45. ncbi The podocyte's response to injury: role in proteinuria and glomerulosclerosis
    S J Shankland
    Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington 98195, USA
    Kidney Int 69:2131-47. 2006
    ..It is the hope that by delineating the events following injury to podocytes, therapies might be developed to reduce the burden of proteinuric renal diseases...
  46. ncbi Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney
    Yves Gorin
    Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    J Biol Chem 280:39616-26. 2005
    ..These data establish a role for Nox4 as the major source of ROS in the kidneys during early stages of diabetes and establish that Nox4-derived ROS mediate renal hypertrophy and increased fibronectin expression...
  47. pmc Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans
    Barry I Freedman
    Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina, USA
    PLoS Genet 7:e1002150. 2011
    ..These analyses reveal a role for FRMD3 in AA T2DN susceptibility and accounting for c22 nephropathy risk variants can assist in detecting DN susceptibility genes...
  48. pmc FGF-23 as a predictor of renal outcome in diabetic nephropathy
    Silvia M Titan
    Sao Paulo University Medical School, Av Dr Eneas de Carvalho Aguiar, 255, Nephrology Department, 05403 000, Sao Paulo, SP, Brazil
    Clin J Am Soc Nephrol 6:241-7. 2011
    ..An important regulator of phosphorus homeostasis, FGF-23 has been shown to independently predict CKD progression in nondiabetic renal disease. We analyzed the relation between FGF-23 and renal outcome in diabetic nephropathy (DN)...
  49. ncbi Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice
    F Y Chow
    Department of Nephrology, Monash Medical Centre, Clayton, Vic, 3168, Australia
    Diabetologia 50:471-80. 2007
    ..Based on these findings, the aim of this study was to examine whether a deficiency in MCP-1 would alter the development of type 2 diabetes and its renal complications...
  50. doi The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential
    Hiroyuki Mori
    Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA
    Biochem Biophys Res Commun 384:471-5. 2009
    ..These results indicate that mTOR activation plays a pivotal role in the development of ESRD and that rapamycin could be an effective therapeutic agent for DN...
  51. ncbi Mouse models of diabetic nephropathy
    Matthew D Breyer
    Division of Nephrology and Department of Medicine, Vanderbilt University Medical School, S3223 MCN, Nashville, TN 37232, USA
    J Am Soc Nephrol 16:27-45. 2005
    ..Establishment of an authentic mouse model of DN will undoubtedly facilitate testing of translational diagnostic and therapeutic interventions in mice before testing in humans...
  52. doi The role of inflammatory cytokines in diabetic nephropathy
    Juan F Navarro-González
    Servicio de Nefrologia, Hospital Universitario Nuestra Senora de Candelaria, Carretera del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain
    J Am Soc Nephrol 19:433-42. 2008
    ..Finally, the recognition of these molecules as significant pathogenic mediators in diabetic nephropathy leaves open the possibility of new potential therapeutic targets...
  53. ncbi Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial
    Michael W Steffes
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Diabetes Care 26:832-6. 2003
    ..Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy)...
  54. pmc Pirfenidone for diabetic nephropathy
    Kumar Sharma
    Center for Renal Translational Medicine, University of California San Diego Veteran Affairs Medical Center, La Jolla, CA 92093 0711, USA
    J Am Soc Nephrol 22:1144-51. 2011
    ..In conclusion, these results suggest that pirfenidone is a promising agent for individuals with overt diabetic nephropathy...
  55. ncbi Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB
    Maristela Lika Onozato
    Division of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan
    Kidney Int 61:186-94. 2002
    ..We tested the hypothesis that Ang II subtype 1 (AT1) receptor activation enhances oxidative stress and nitrotyrosine deposition in the kidneys of rats with diabetes mellitus (DM)...
  56. ncbi The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?
    R E Gilbert
    University of Melbourne, Department of Medicine, West Heidelberg, Victoria, 3081, Australia
    Kidney Int 56:1627-37. 1999
    ..Continued exploration into tubulointerstitial disease in addition to glomerular injury in diabetes may help provide further insights into the pathogenesis of diabetic nephropathy and additional targets for therapeutic intervention...
  57. ncbi Renoprotective role of the vitamin D receptor in diabetic nephropathy
    Z Zhang
    Division of Biological Sciences, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Kidney Int 73:163-71. 2008
    ..1,25-Dihydroxyvitmain D3 also suppressed HG-induced activation of the RAS and TGF-beta in mesangial and juxtaglomerular cells. Our study suggests that receptor-mediated vitamin D actions are renoprotective in diabetic nephropathy...
  58. ncbi Aldose reductase and the role of the polyol pathway in diabetic nephropathy
    M Dunlop
    Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    Kidney Int Suppl 77:S3-12. 2000
    ..Aldose reductase may detoxify these compounds. We investigated this aspect in a transgenic rat model with human aldose reductase cDNA under the control of the cytomegalovirus promoter with tubular expression of transgene...
  59. doi The global burden of diabetes and its complications: an emerging pandemic
    Susan van Dieren
    Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
    Eur J Cardiovasc Prev Rehabil 17:S3-8. 2010
    ..Global excess mortality attributable to diabetes in adults was estimated to be 3.8 million deaths...
  60. pmc Temporal trends in the prevalence of diabetic kidney disease in the United States
    Ian H De Boer
    Kidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA 98104, USA
    JAMA 305:2532-9. 2011
    ..Over time, the prevalence of diabetic kidney disease (DKD) may increase due to the expanding size of the diabetes population or decrease due to the implementation of diabetes therapies...
  61. ncbi Diabetic nephropathy: mechanisms of renal disease progression
    Yashpal S Kanwar
    Department of Pathology, Northwestern University School of Medicine, Chicago, IL 60611, USA
    Exp Biol Med (Maywood) 233:4-11. 2008
    ....
  62. ncbi Rapamycin prevents early steps of the development of diabetic nephropathy in rats
    Yi Yang
    Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
    Am J Nephrol 27:495-502. 2007
    ..This study was designed to determine the therapeutic effects of rapamycin on diabetic nephropathy at an early stage...
  63. pmc Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications p
    Saul Genuth
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    Diabetes 54:3103-11. 2005
    ..Glycation and subsequent AGE formation may explain the risk of these complications associated with prior A1C and provide a rational basis for the phenomenon of "metabolic memory" in the pathogenesis of these diabetes complications...
  64. ncbi Diabetes and advanced glycation endproducts
    H Vlassara
    Department of Geriatrics, Mount Sinai School of Medicine, NY 10029, USA
    J Intern Med 251:87-101. 2002
    ..The final disposal of AGE depends on renal clearance. Promising pharmacologic strategies to prevent AGE formation, reduce AGE toxicity, and/or inactivate AGE are under investigation...
  65. ncbi Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes
    Shinichi Okada
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Diabetes 52:2586-93. 2003
    ..Moreover, expressions of TGF-beta and type IV collagen in glomeruli were also suppressed in diabetic ICAM-1(-/-) mice. These results suggest that ICAM-1 is critically involved in the pathogenesis of diabetic nephropathy...
  66. ncbi Reactive oxygen species-regulated signaling pathways in diabetic nephropathy
    Hi Bahl Lee
    Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea
    J Am Soc Nephrol 14:S241-5. 2003
    ..Future studies elucidating various other target molecules activated by ROS in renal cells cultured under high glucose or in diabetic kidney will allow a better understanding of the final cellular responses to high glucose...
  67. ncbi Characterization of susceptibility of inbred mouse strains to diabetic nephropathy
    Zhonghua Qi
    Veterans Administration Medical Center, Nashville, TN 37212, USA
    Diabetes 54:2628-37. 2005
    ..DBA/2J and KK/HlJ mice are more prone to diabetic nephropathy, whereas the most widely used C57BL/6J mice are relatively resistant to development of diabetic nephropathy...
  68. ncbi The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    H H Parving
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 345:870-8. 2001
    ..02). CONCLUSIONS: Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria...
  69. ncbi Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    Dick de Zeeuw
    Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
    Circulation 110:921-7. 2004
    ..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
  70. doi Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice
    Fernando E Ezquer
    Instituto de Ciencias, Facultad de Medicina, Clinica Alemana Universidad Del Desarrollo, Santiago, Chile
    Biol Blood Marrow Transplant 14:631-40. 2008
    ..Our preclinical results suggest bone marrow-derived MSC transplantation as a cell therapy strategy to treat type 1 diabetes and prevent diabetic nephropathy, its main complication...
  71. pmc Human recombinant ACE2 reduces the progression of diabetic nephropathy
    Gavin Y Oudit
    Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Diabetes 59:529-38. 2010
    ..Inhibition of ACE2 function accelerates diabetic kidney injury, whereas renal ACE2 is downregulated in diabetic nephropathy. We examined the ability of human recombinant ACE2 (hrACE2) to slow the progression of diabetic kidney injury...
  72. pmc Angiopoietin-1 is essential in mouse vasculature during development and in response to injury
    Marie Jeansson
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    J Clin Invest 121:2278-89. 2011
    ..These findings redefine our understanding of the biological roles of angiopoietin-1: it is dispensable in quiescent vessels but has a powerful ability to modulate the vascular response after injury...
  73. doi Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy
    M Sedeek
    Kidney Research Centre, Ottawa Hospital Research Institute and Deptartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Am J Physiol Renal Physiol 299:F1348-58. 2010
    ..These findings implicate Nox4-based NADPH oxidase in molecular mechanisms underlying fibrosis in type 2 diabetic nephropathy...
  74. doi Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy
    G H Tesch
    Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
    Am J Physiol Renal Physiol 300:F301-10. 2011
    ..This review summarizes the advances in knowledge gained from studies in genetically modified db/db mice and treatment of db/db mice with novel therapeutic agents...
  75. pmc The targeted podocyte
    Agnes B Fogo
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    J Clin Invest 121:2142-5. 2011
    ..In this issue of the JCI, two interesting studies of podocyte-specific manipulation of the mTOR system shed light on the complexity of this pathway in the podocyte...
  76. doi Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy
    Jin Ji Li
    Department of Internal Medicine, College of Medicine, Brain Korea 21 for Medical Science, Yonsei University, Seoul, Korea 120 752
    Am J Physiol Renal Physiol 297:F200-9. 2009
    ..These findings provide a new perspective on the renoprotective effects of Col in DN...
  77. ncbi ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice
    M J Soler
    Division of Nephrology and Hypertension, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Kidney Int 72:614-23. 2007
    ..Our study shows that chronic pharmacologic ACE2 inhibition worsens glomerular injury in streptozotocin-induced diabetic mice in association with increased ACE expression...
  78. ncbi Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy
    Fuad N Ziyadeh
    Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    Curr Diabetes Rev 4:39-45. 2008
    ....
  79. pmc BTBR Ob/Ob mutant mice model progressive diabetic nephropathy
    Kelly L Hudkins
    Department of Pathology, University of Washington, Seattle, Washington, USA
    J Am Soc Nephrol 21:1533-42. 2010
    ..In summary, BTBR ob/ob mice develop a constellation of abnormalities that closely resemble advanced human DN more rapidly than most other murine models, making this strain particularly attractive for testing therapeutic interventions...
  80. doi Diabetic nephropathy: important pathophysiologic mechanisms
    G Soldatos
    Vascular Divsion, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road, Central Melbourne, Victoria 8008, Australia
    Diabetes Res Clin Pract 82:S75-9. 2008
    ....
  81. ncbi Differential expression of nephrin according to glomerular size in early diabetic kidney disease
    Jin Ju Kim
    Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemoon Gu, Seoul, Korea 120 752
    J Am Soc Nephrol 18:2303-10. 2007
    ..Furthermore, more hypertrophied glomeruli with lesser nephrin expression may be responsible for albuminuria in the early stage of DN...
  82. doi The RAAS in the pathogenesis and treatment of diabetic nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Nat Rev Nephrol 6:319-30. 2010
    ..Such findings will have major implications, particularly in settings where money and facilities are limited and in settings where renal replacement therapy is not available and the prevention of kidney failure is life saving...
  83. pmc Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
    Nina Reiniger
    1Department of Surgery, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
    Diabetes 59:2043-54. 2010
    ....
  84. pmc Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients
    Limei Liu
    Department of Endocrinology and Metabolism, Shanghai JiaoTong University Affiliated Sixth People s Hospital, Shanghai Diabetes Institute, Shanghai, China
    Diabetes Care 33:144-9. 2010
    ..To determine whether the Pro12Ala polymorphism, alone or in combination with smoking, contributes to the development of diabetic nephropathy, a case-control study was performed in 760 Chinese patients with type 2 diabetes...
  85. ncbi Adaptation to hypoxia in the diabetic rat kidney
    C Rosenberger
    Nephrology and Medical Intensive Care, Charite University Clinic, Augustenburger Platz 1, Berlin 13353, Germany
    Kidney Int 73:34-42. 2008
    ..Our data suggest that both regional hypoxia and hypoxia adaptation transiently occur in early stages of experimental diabetes, largely dependent on hyperglycemia or after contrast media. Tempol may augment the HIF response in diabetes...
  86. ncbi Clinical practice. Nephropathy in patients with type 2 diabetes
    Giuseppe Remuzzi
    Unit of Nephrology, Ospedali Riuniti di Bergamo, Italy
    N Engl J Med 346:1145-51. 2002
  87. ncbi Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats
    Sameer Sharma
    Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160 014, India
    Pharmacology 76:69-75. 2006
    ..The present study reinforces the important role of oxidative stress in diabetic kidney and points towards the possible antioxidative mechanism being responsible for the renoprotective action of resveratrol...
  88. ncbi A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy
    Myung Ja Lee
    Dept of Nephrology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Am J Physiol Renal Physiol 292:F617-27. 2007
    ..AMPK is a newly identified regulator of renal hypertrophy in diabetes...
  89. ncbi Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease
    S Menini
    Department of Clinical Sciences, La Sapienza University, Viale del Policlinico, 155 00161, Rome, Italy
    Diabetologia 50:2591-9. 2007
    ..This study aimed to assess the rate of glomerular cell death and its relationship with renal functional, structural and molecular changes in rats with experimental diabetes...
  90. ncbi Rodent models of streptozotocin-induced diabetic nephropathy
    Greg H Tesch
    Department of Nephrology, Monash University, Monash Medical Centre, Clayton, Victoria, Australia
    Nephrology (Carlton) 12:261-6. 2007
    ....
  91. pmc The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential
    Hai Yong Chen
    Department of Medicine and Therapeutics and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China
    Diabetes 60:590-601. 2011
    ..The current study tests the hypothesis that Smad7 may play a protective role and has therapeutic potential for diabetic kidney disease...
  92. pmc Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes
    S C Thomson
    Department of Medicine, Division of Nephrology Hypertension, University of California at San Diego and Veterans Affairs Medical Center, 3350 La Jolla Village Drive, San Diego, California 92161 9151, USA
    J Clin Invest 107:217-24. 2001
    ....
  93. pmc Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria
    Chunsun Dai
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Am Soc Nephrol 20:1997-2008. 2009
    ..These results suggest that targeting hyperactive Wnt/beta-catenin signaling may represent a novel therapeutic strategy for proteinuric kidney diseases...
  94. ncbi Diabetic nephropathy: diagnosis, prevention, and treatment
    Jorge L Gross
    Endocrine Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
    Diabetes Care 28:164-76. 2005
    ....
  95. ncbi Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury
    Fiona Chow
    Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
    Kidney Int 65:116-28. 2004
    ..Therefore, we examined whether macrophages may promote the progression of type 2 diabetic nephropathy in db/db mice...
  96. pmc Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes
    Monika A Niewczas
    Research Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    J Am Soc Nephrol 23:507-15. 2012
    ..In conclusion, elevated concentrations of circulating TNFRs in patients with type 2 diabetes at baseline are very strong predictors of the subsequent progression to ESRD in subjects with and without proteinuria...
  97. pmc Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway
    Munehiro Kitada
    Division of Diabetes and Endocrinology, Kanazawa Medical University, Kahoku gun, Ishikawa, Japan
    Diabetes 60:634-43. 2011
    ..This study examined the renoprotective effects of RSV in db/db mice, a model of type 2 diabetes...
  98. doi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
    ..In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain...
  99. ncbi Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator
    Fuad N Ziyadeh
    Penn Center for Molecular Studies of Kidney Diseases, Renal Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Soc Nephrol 15:S55-7. 2004
    ..These studies argue strongly in support of the hypothesis that overactivity of the TGF-beta system in the kidney is a crucial mediator of diabetic renal hypertrophy and mesangial matrix expansion...
  100. pmc Urinary proteomics in diabetes and CKD
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    J Am Soc Nephrol 19:1283-90. 2008
    ..In conclusion, this study shows that analysis of the urinary proteome may allow early detection of diabetic nephropathy and may provide prognostic information...
  101. pmc Oxidative stress in diabetic nephropathy
    N Kashihara
    Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Curr Med Chem 17:4256-69. 2010
    ....

Research Grants74

  1. Correction of glutathione deficiency for treatment of diabetic nephropathy
    Paolo Fanti; Fiscal Year: 2013
    ....
  2. New insights in mechanisms of renal injury
    Balakuntalam S Kasinath; Fiscal Year: 2013
    ..Upstream regulators and downstream effectors of GSK 3beta in transcription and translation pathways involved in matrix protein synthesis will be explored in renal tissues as stated in Aim 1. ..
  3. Role of Peroxidasin in Glomerular Matrix Homeostasis
    Gautam Bhave; Fiscal Year: 2013
    ..Ultimately, Dr. Bhave hopes to translate his seminal biochemical discovery into an independent line of investigation examining the role of peroxidasin in matrix remodeling and expansion in renal disease. ..
  4. N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
    Paolo Fanti; Fiscal Year: 2011
    ..Throughout the trial, we will monitor the safety and tolerability of this combination treatment. ..
  5. Modifiers of Cyst Progression in Polycystic Kidney Disease
    Phillip Darwin Bell; Fiscal Year: 2013
    ..Thus there is a compelling reason to focus on this disease and its effective treatment or cure, which would greatly benefit the VA patient population. ..
  6. Metabolic regulation of diabetic nephropathy
    Karen Block; Fiscal Year: 2013
    ..This work may have major therapeutic implications. ..
  7. Role of Endocytosis and Vesicular Trafficking in Podocyte Health and Filter Integ
    Puneet Garg; Fiscal Year: 2012
    ....
  8. Novel drug VS-105 for treatment of diabetic nephropathy
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2012
    ....
  9. Health Care Disparities in the Pacific Islands Pacific Regional Medical Conferenc
    SAIED SAFABAKHSH; Fiscal Year: 2011
    ....
  10. Mechanism of eNOS Uncoupling in the Renal Microvasculature
    YVES CLAUDE GORIN; Fiscal Year: 2013
    ..abstract_text> ..
  11. The role of SIRT1/FOXO4 pathway in podocyte apoptosis of diabetes mellitus
    PETER YENLUNG CHUANG; Fiscal Year: 2013
    ..This study could give new insight into the pathogenesis of diabetic nephropathy and provide targets for novel therapy. ..
  12. Mechanisms of tubular atrophy in renal disease
    Jeffrey R Schelling; Fiscal Year: 2012
    ..The purpose of this project is to determine why kidneys fail. In particular, we plan to study biochemical pathways that prevent kidneys cells from dying, which may lead to new therapies to halt the progression of kidney diseases. ..
  13. Epidemiology of Retinopathy and other Complications in Long Term Type 1 Diabetes
    Michael Y Tsai; Fiscal Year: 2013
    ..These data will be important to patients and their physicians in developing new interventions for managing type 1 diabetes and to public health practitioners charged with delivering preventive care. ..
  14. VITAMIN D DEFICIENCY, INSULIN RESISTANCE AND CARDIOVASCULAR DISEASE
    Carlos Bernal-Mizrachi; Fiscal Year: 2013
    ....
  15. Mechanism of Renal Cell Injury in Diabetes
    Goutam Ghosh Choudhury; Fiscal Year: 2013
    ....
  16. Phenotypes of diabetic kidney disease and the relationship to retinal pathology
    Amy Mottl; Fiscal Year: 2013
    ..This will form the basis for an R01 which will extend these robust techniques to a larger cohort and provide definitive data regarding the phenotypes of diabetic complications of the kidney and eye and their relationship to each other. ..
  17. Omega 3 Fatty Acid Supplementation in Diabetic Kidney Disease
    EDGAR RAYMOND MILLER; Fiscal Year: 2010
    ..We are hopeful that omega-3 fatty acid supplements may add to current therapies that help protect against progression of kidney disease, a common and devastating complication of diabetes. ..
  18. Integrated Cardio-Renal Risk Prediction Models in Type 1 Diabetes
    Marian J Rewers; Fiscal Year: 2010
    ..As a result, it is of critical public health importance to discover and validate new biomarkers for cardio-renal disease among adults with type 1 diabetes. ..
  19. NITRIC OXIDE AND OXYGENATION IN DIABETIC KIDNEYS
    NILS AXEL FREDRIK PALM; Fiscal Year: 2010
    ..abstract_text> ..
  20. Novel Models of Diabetic Nephropathy
    Moshe Levi; Fiscal Year: 2010
    ....
  21. Heparan Sulfate Proteoglycans in Human Hematopoiesis
    Pankaj Gupta; Fiscal Year: 2013
    ....
  22. The Role of Cyclooxygenase-2 in Podocyte Injury in Diabetic Nephropathy
    Raymond Harris; Fiscal Year: 2013
    ..It is hoped that such studies may lead to targeted therapeutic options with a favorable risk-benefit profile that can prevent or slow the development of diabetic nephropathy. ..
  23. Regulation of Nox Enzymes by Calcium and Novel Subunits
    JOHN DAVID LAMBETH; Fiscal Year: 2013
    ..A molecular understanding of the regulation of Nox/Duox enzymes will provide key information that will be key to preventing excess or inappropriate ROS generation and mitigating the course of these diseases. ..
  24. Regulation of Nox Enzymes by Calcium and Novel Subunits
    J Lambeth; Fiscal Year: 2009
    ..A molecular understanding of the regulation of Nox/Duox enzymes will provide key information that will be key to preventing excess or inappropriate ROS generation and mitigating the course of these diseases. ..
  25. Podocyte TRB in Diabetic Nephropathy
    ROBYN A CUNARD; Fiscal Year: 2012
    ..Accordingly, we believe that TRB3 may prove to be an important therapeutic target in diabetic nephropathy. ..
  26. STUDIES ON THE STRUCTURE OF BASEMENT MEMBRANES
    BILLY GERALD HUDSON; Fiscal Year: 2013
    ..The basic science knowledge of the structure and assembly of collagen IV networks allow us to have a better understanding of the pathogenesis of kidney diseases. ..
  27. Randomized trial of vitamin D and omega-3 fatty acids for diabetic kidney disease
    Ian H De Boer; Fiscal Year: 2013
    ..This study will evaluate whether vitamin D3 and/or omega-3 fatty acids are safe and effective interventions to reduce the burden of DKD among the large and growing diabetic population. ..
  28. The Rho GTPases Cdc42 and Rac1 in diabetic Nephropathy
    JEFFREY BENTON HODGIN; Fiscal Year: 2013
    ....
  29. Role of Par1 Polarity Proteins in Podocyte Development and Glomerular Disease
    KIMBERLY JEAN REIDY; Fiscal Year: 2013
    ....
  30. MASP-2 Antibodies for Diabetic Neuropathy
    THOMAS ANTON DUDLER; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: Tis rojectseekstoexlore heuseo-fMaSniP-2 atioytherayto revet ortrea eroahiccomlicaiosofdiaees. ..
  31. p66/Insulin Like Growth Factor-1 Reno-Protection in Diabetes
    LEONARD GERALD MEGGS; Fiscal Year: 2010
    ....
  32. Ambulatory Case and Preventable Hospitalizations in Diabetic Kidney Disease
    Chin Lin Tseng; Fiscal Year: 2013
    ..Predictive models for risks of PQIs will be developed and validated for model predictability. ..
  33. Renal Cell Response in Diabetes
    Hanna E Abboud; Fiscal Year: 2012
    ..It is our hope that identifying specific sources of oxygen radicals will allow targeted therapy to prevent diabetic nephropathy. ..
  34. PATHOGENESIS OF DIABETIC NEPHROPATHY
    Yashpal S Kanwar; Fiscal Year: 2013
    ..It is anticipated that the characterization of GX-SIRT pathway would aid in devising novel therapeutic strategies to decelerate tubulo-interstitial injury in DN. ..
  35. Role of 12-Lipoxygenase and Growth Factors in Diabetic Nephropathy
    Rama Natarajan; Fiscal Year: 2013
    ....
  36. Associations among RAAS Inhibitors, Residual Kidney Function, and CV Events in PD
    Jenny I Shen; Fiscal Year: 2013
    ..Further, the size of the database will allow us to study relevant patient subgroups. ..
  37. Role of NG2 in diabetic nephropathy
    Vesselina G Cooke; Fiscal Year: 2010
    ..Collectively these studies will elucidate novel mechanisms associated with early diabetic nephropathy and open new avenues to explore therapies. ..
  38. Impact of Vitamin D on Diabetic Kidney Disease in African Americans
    VANESSA ASTRUD DIAZ; Fiscal Year: 2012
    ..This project is an attempt to determine the impact of vitamin D supplementation on the progression of early stage diabetic kidney disease. ..
  39. Training Grant in Renal Function and Disease
    Phillip Darwin Bell; Fiscal Year: 2013
    ..Thus, this training program addresses a critical public health problem that requires an integrated, broad basedapproach. ..
  40. Tissue-Specific Metabolic Reprogramming in Diabetic Complications
    Subramaniam Pennathur; Fiscal Year: 2011
    ..We will utilize in vivo and in vitro analysis of mouse models and human patients to achieve these goals. ..
  41. Selectin inhibitor therapeutics for blood flow related complications of diabetes
    John L Magnani; Fiscal Year: 2010
    ....
  42. Identifying urinary biomarkers for early type 2 diabetic nephropathy
    Maryam Afkarian; Fiscal Year: 2013
    ..We plan to find urine marker proteins that can be used to detect early signs of diabetic damage to the kidneys, when it is more likely to be stopped or reversed. ..
  43. Mast-Cell Renin and Local ANG II Formation
    RANDI BETH SILVER; Fiscal Year: 2010
    ..If our hypothesis is proven correct then we will have identified a novel therapeutic target (mast cell renin) for ameliorating renal function in chronic kidney disease. ..
  44. Urinary Biomarkers in Biopsy Defined Early Nephropathy in Types 1 and 2 Diabetes
    S MICHAEL MAUER; Fiscal Year: 2013
    ....
  45. AT1 Receptors in Renal Microvascular Physiology
    LISA HARRISON BERNARD; Fiscal Year: 2009
    ..abstract_text> ..
  46. Multi-factorial Intervention to Slow Progression of Diabetic Kidney Disease
    Uptal D Patel; Fiscal Year: 2013
    ....
  47. Glucose Modifications of Proteins in Diabetic Nephropathy
    BILLY GERALD HUDSON; Fiscal Year: 2013
    ....
  48. Role of Protein Acetylation in Diabetic kidney Disease
    John C He; Fiscal Year: 2013
    ..The proposed studies will help us to understand how acetylation of TFs affects their target gene expression in diabetic kidneys and determine whether BrDi could be developed as a new class of drugs to treat patients with DKD. ..
  49. KIM-1, microparticles and diabetic tubular injury
    Xueying Zhao; Fiscal Year: 2013
    ..Our studies will also shed light on KIM-1/KIM-MPs as attractive targets for kidney disease management. ..
  50. ADENOSINE AND RENAL INJURY
    MARK OKUSA; Fiscal Year: 2009
    ..These experiments also will shed light on the role of inflammation in the etiology of DN and provide insights into other potential anti-inflammatory therapeutic strategies. ..
  51. A rapid, sensitive assay for quantitation of human prorenin in biological samples
    DUANE ELLINGTON DAY; Fiscal Year: 2010
    ..This assay will then be adapted to the high throughput Luminex system for eventual use in the clinical laboratory, offering significant advantages of speed and sensitivity over current methods of prorenin quantitation. ..
  52. GDNF and Ret are critical for glomerular development, maintenance, and protection
    CYNTHIA TSUI; Fiscal Year: 2013
    ..The goal of our proposal Is to understand these mechanisms and to discover molecules controlling the growth and health of the podocyte with the intent that this knowledge will facilitate the development of new therapeutic strategies...
  53. GLOMERULAR AND TUBULAR FUNCTION IN THE DIABETIC KIDNEY
    Scott C Thomson; Fiscal Year: 2013
    ..There is a longstanding idea that the early hemodynamic phenotype provokes the subsequent demise of a diabetic kidney. This research focuses on that early stage of diabetes, before there is injury or sclerosis. ..
  54. Peptide mimics of BMP7 for treatment of renal fibrosis and diabetic nephropathy
    William J Dower; Fiscal Year: 2012
    ....
  55. Role of SGLT3 in diabetes-mediated increased renal sodium reabsorption
    Niloofar M Tabatabai; Fiscal Year: 2013
    ..The proposed in vitro and in vivo studies are designed to investigate the role of SGLT3 as a novel glucose-stimulated Na+ transporter that may play role in the enhanced Na+ reabsorption in diabetes. ..
  56. Treatment of Kidney Disease in Diabetes and Obesity
    Moshe Levi; Fiscal Year: 2013
    ..abstract_text> ..
  57. Integrative Biology of Childhood Kidney Disease
    ELLIS DAVID AVNER; Fiscal Year: 2011
    ..Therefore, a clear aim of both projects of this proposed RCEPN is the development of therapies which prevent or modulate this progression. ..
  58. Training Program in Nephrology Research
    Alfred K Cheung; Fiscal Year: 2011
    ..Basic researcher trainees experience a large faculty group with complementary research interests. All trainees spend at least two years devoted to research. ..
  59. Interactions of intrarenal dopamine and cyclooxygenase-2
    Raymond Harris; Fiscal Year: 2012
    ..The physiologic and pathophysiologic interactions of these systems, the intrarenal dopaminergic system, the renin angiotensin system and the cyclooxygenase-2 system, are the focus of the proposed studies. ..
  60. Cross-talk between growth hormone and inflammation pathways in kidney damage
    Karen T Coschigano; Fiscal Year: 2010
    ..Furthermore, this project provides an excellent training environment for undergraduate, graduate and medical students, including underrepresented minorities, as they pursue careers in the health-related fields. ..
  61. Role of TSC-mTORC1 pathway for podocyte injury in diabetic nephropathy
    Ken Inoki; Fiscal Year: 2013
    ..Completion of this project will not only reveal a novel molecular mechanism for podocyte injury but also set the stage for additional studies to explore new therapeutic approaches to the treatment of DN. ..
  62. Upstream Stimulatory Factor 2 regulation of renin in diabetic nephropathy
    Shuxia Wang; Fiscal Year: 2013
    ..abstract_text> ..
  63. Podocytes and oxidative stress in diabetic kidney
    Paul N Epstein; Fiscal Year: 2010
    ..These mice will be used to assess the role of ROS damage to the podocyte in the changing gene expression and deteriorating structure and function that lead to diabetic end stage renal disease. ..
  64. Impact of Puberty on the Kidney in Diabetes
    PASCALE LANE; Fiscal Year: 2005
    ..Health implications: New treatments to prevent diabetic kidney disease, the most important cause of kidney failure in the US, may emerge from a better understanding of a naturally protected state such as the prepubertal animal. ..
  65. ROLE OF GLUCOSE IN hAT1 GENE EXPRESSION
    Thomas Thekkumkara; Fiscal Year: 2009
    ..With this information we are hoping to obtain a better understanding of the receptor action, and also a direction in the management and treatment of kidney diseases in diabetes. ..
  66. Poly(ADP-ribose) polymerase in diabetic nephropathy
    IRINA OBROSOVA; Fiscal Year: 2006
    ..abstract_text> ..
  67. Cellular Physiology of Podocytes
    Stuart E Dryer; Fiscal Year: 2010
    ..Practically nothing is currently known about the effects of insulin on podocytes, which limits what we can know about diabetic nephropathy, especially in its earliest stages. ..
  68. Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy
    Kumar Sharma; Fiscal Year: 2005
    ....
  69. GLYCOSYLATED PROTEINS--DEVELOPING DIABETIC KIDNEY
    Edward Skolnik; Fiscal Year: 1993
    ..These findings would provide the rationale for designing therapies directed at preventing this chain of events...
  70. Proteome of Glomerular Cells in Diabetic Nephropathy
    Paul Voziyan; Fiscal Year: 2007
    ..abstract_text> ..
  71. DIABETIC NEPHROPATHY IN MINNESOTA AMERICAN INDIANS
    William Keane; Fiscal Year: 1991
    ....
  72. Genetics of Diabetic Nephropathy in Mexican-Americans a*
    Susanne Nicholas; Fiscal Year: 2006
    ..The final year of the project will focus more heavily on manuscript preparation. Dr. Nicholas will be directly involved in all aspects of the project. ..
  73. SOY PROTEIN USE IN EARLY DIABETIC NEPHROPATHY
    Paolo Fanti; Fiscal Year: 2001
    ..Additionally, this study will provide solid rationale for future animal and in vitro studies aimed at revealing the mechanism(s) that underlie the proposed beneficial effects of soyfoods in kidney disease. ..
  74. THROMBOSPONDIN IN GLUCOSE-MEDIATED TGFB UPREGULATION
    Joanne Murphy Ullrich; Fiscal Year: 2001
    ..These studies are part of a larger initiative to understand the molecular mechanisms involved in fibrosis. ..